FDA approves Akorn-Strides's two ANDAs for Famotidine Injection (Pharmaceutical Business Review)
Akorn-Strides has announced the approvals of two abbreviated new drug applications for Famotidine Injection USP, 20 mg/2mL single-dose vials and 40 mg/4mL and 200 mg/20mL multiple-dose vials.

AspenBio Pharma Commences FDA Clinical Trial For AppyScoreTM Appendicitis Blood Test (Medical News Today)
AspenBio Pharma, Inc. (NASDAQ: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, has officially initiated a clinical trial to support the FDA 510(k) application for the AppyScore Human Appendicitis blood-based diagnostic test.